Partial
Partially Aligned
Patient Risk:
Low
Summary
Label-supported claims (omega-3/icosapent ethyl identity and specific TG/CV risk-reduction indications) are partially accurate, but multiple material non-label claims (cost, discount cards, assistance, and payer/discount retailers) are unsupported by the provided prescribing information. Safety-critical sections needed for full audit were not provided.
Category Scores
Accurate Statements
Vascepa is a prescription medication containing omega-3 fatty acids.
11 DESCRIPTION (icosapent ethyl is an ethyl ester of the omega-3 fatty acid eicosapentaenoic acid (EPA)); also described as a lipid-regulating agent in label description.
Vascepa is used to reduce the risk of cardiovascular events.
1 INDICATIONS AND USAGE (reduce risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adults with elevated triglyceride levels under specified conditions).
Vascepa (icosapent ethyl) has been shown to reduce triglyceride levels.
1 INDICATIONS AND USAGE (adjunct to diet to reduce TG levels in adults with severe hypertriglyceridemia; adjunct to maximally tolerated statin therapy in adults with elevated TG to reduce CV risk).
Vascepa is also known as icosapent ethyl.
11 DESCRIPTION (active ingredient: icosapent ethyl) and overall labeling context (VASCEPA (icosapent ethyl)).
Unsupported Statements
Vascepa is used to treat high triglycerides.
Partially supported: label specifies adjunct to diet for severe (≥ 500 mg/dL) hypertriglyceridemia and adjunct to statin therapy in specific adults with elevated TG (≥ 150 mg/dL) for CV risk reduction; the broad wording 'treat high triglycerides' is not fully aligned with the label limitation/population and adjunct-to-therapy language.
Vascepa has been shown to improve cardiovascular health.
Not supported as stated: provided label wording specifies reduction in particular cardiovascular risk endpoints rather than the broad claim of 'improve cardiovascular health.'
The average monthly cost of Vascepa can range from $300 to $500, depending on the dosage and location.
No pricing/cost information is present in the provided label sections.
The Vascepa Savings Card provides discounts of up to $50 per prescription for eligible patients.
No discount-card terms are present in the provided label sections.
The Vascepa Patient Assistance Program provides free Vascepa to eligible patients who are uninsured or underinsured.
No patient assistance/free-product program terms are present in the provided label sections.
The Vascepa Co-Pay Program offers co-pay assistance to eligible patients who have commercial insurance.
No co-pay program terms are present in the provided label sections.
Vascepa is covered under Medicare Part D.
No payer coverage information is present in the provided label sections.
Vascepa may be covered under Medicaid.
No payer coverage information is present in the provided label sections.
Vascepa may be covered under the Veterans Administration.
No payer coverage information is present in the provided label sections.
GoodRx offers discounts on Vascepa and other prescription medications.
No third-party retailer/discount information is present in the provided label sections.
RxSaver offers discounts on Vascepa and other prescription medications.
No third-party retailer/discount information is present in the provided label sections.
Walmart Pharmacy offers discounts on Vascepa and other prescription medications.
No third-party retailer/discount information is present in the provided label sections.
Coupons.com offers coupons and discount codes for Vascepa and other prescription medications.
No coupon/discount guidance from these entities is present in the provided label sections.
RetailMeNot offers coupons and discount codes for Vascepa and other prescription medications.
No coupon/discount guidance from these entities is present in the provided label sections.
Groupon offers coupons and discount codes for Vascepa and other prescription medications.
No coupon/discount guidance from these entities is present in the provided label sections.
The Vascepa Access Program provides free Vascepa to eligible patients who are uninsured or underinsured.
No patient assistance/free-product program terms are present in the provided label sections.
The Vascepa Co-Pay Program offers co-pay assistance to eligible patients who have commercial insurance.
No co-pay program terms are present in the provided label sections.
Manufacturer discounts and patient assistance programs can provide significant savings on Vascepa.
No manufacturer discount/savings language is present in the provided label sections.
Government programs, such as Medicare Part D and Medicaid, can provide access to Vascepa at a lower cost.
No payer access/cost language is present in the provided label sections.
Online pharmacies and discount stores can offer discounts and promotions on Vascepa.
No distribution/discount/promotion statements are present in the provided label sections.
Coupons and discount codes can be used to access Vascepa at a lower cost.
No coupon/discount guidance is present in the provided label sections.
Manufacturer-sponsored programs can provide free Vascepa to eligible patients.
No manufacturer-sponsored free-product program statements are present in the provided label sections.
Contradictions
Important Omissions
Contraindications / boxed warning / dosing & administration / warnings & precautions / monitoring / detailed use in specific populations were not provided in the supplied label excerpts, so safety-critical alignment cannot be assessed.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims are primarily about cost/discount programs and broad phrasing of effectiveness. However, safety-critical label sections needed to evaluate contraindications, boxed warnings, dosing, and precautions were not included in the provided information, limiting the completeness of the audit.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims (cost/discount cards, patient assistance, payer coverage, and third-party discount retailers) are not supported by the provided FDA label excerpts; also one effectiveness claim uses broad language not matching label endpoints.
Suggested Improvement
Limit claims to on-label content supported by the provided sections (e.g., the specific indications and CV risk-reduction endpoints, and the identification of icosapent ethyl as the active ingredient) and remove or qualify unsupported non-label pricing/coverage/discount-program statements unless the full label or authorized prescribing materials provide them.